logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

iBionext announces the final closing of 90 million euros for its fund iBionext Growth Fund

February 14, 2018Press releasesIbionext

Dedicated to the creation and development of disruptive healthcare start-ups

Paris, February 14th 2018 – iBionext, a management company and start-up studio specializing in the creation and development of disruptive healthcare start-ups, today announced that it has completed the closing of its fund iBionext Growth Fund for a total of 90 million euros.

After a first closing of 46 million euros, completed 6 months after the creation of iBionext, the fund has attracted new top tier investors, alongside historical investors which have strongly strengthened their commitments. iBionext Growth Fund is supported by around 20 professional investors including leading international industrials, family offices, pension funds and health insurance companies and institutional investors, alongside the Biotech Healthcare Acceleration Fund (FABS) managed by Bpifrance as part of the Investments for the Future Program (PIA) led by the General Secretariat for Investment (SGPI).

iBionext Growth Fund is a new and unique approach to financing growth. Its novel strategy is focused on financing a small and de-risked portfolio of high-potential start-ups, enabling their rapid growth.

The Fund co-created and invested in 5 start-ups that offer revolutionary solutions for unmet medical or industrial needs. These 5 start-ups (Chronocam, Chronolife, Tilak Healthcare, BrainEver, Brainiac) are now in the midst of accelerating their development and are aiming to start clinical trials and / or commercialization activities, leveraging the knowledge and experience of iBionext. A sixth and last project is currently being selected by the iBionext start-up studio team.

iBionext has privileged access to breakthrough technologies in healthcare, through its network of scientists and experts from prestigious research and development centers around the world. Grouped on a single site in Paris, the “Passage de l’innovation”, iBionext companies constitute a unique ecosystem, conducive to expertise pooling and knowledge sharing.

Alexia Perouse, Managing Director and Partner of iBionext, commented: “In 18 months, we have achieved all the commitments we made when iBionext was created, and deployed most of our portfolio in neuromorphism and the convergence of health disciplines. We are delighted to have generated such momentum around our new concept of start-up studio and we thank our investors for their trust. The renewed commitments from our historical investors and the size of the tickets invested speak to the attractiveness of HealthTech.”

About iBionext: https://ibionext.com/

About Bpifrance: www.bpifrance.fr

 

For more information:

www.ibionext.com, @iBionext

contact@ibionext.com, +33 1 76 21 47 50

Press contact

Annie-Florence Loyer – afloyer@newcap.fr – +33 1 44 71 00 12 / +33 6 88 20 35 59

 General Secretariat for Investment (SGPI)

Vincent Deshayes – vincent.deshayes@pm.gouv.fr – +33 1 42 75 64 29

Bpifrance

Nicolas Jehly – nicolas.jehly@bpifrance.fr – +33 1 41 79 95 12

Previous post Bernard Gilly dans Capital Finance “Biotechs et medtechs tricolores briguent davantage de lumière” Next post Video of Alexia Perouse : Closing of iBionext Growth Fund

SEARCH

ARCHIVES

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (67)

LATEST NEWS

  • Théa partners with Tilak Healthcare to promote OdySight: First remote monitoring solution for ophthalmology June 29, 2022
  • GrAI Matter Labs Unveils Life-Ready AI with GrAI VIP at GLOBAL INDUSTRIE May 16, 2022
  • Rigshospitalet, the main hospital in Denmark based in Copenhagen, collaborate with Chronolife for a clinical investigation in Oncology March 31, 2022
  • Europrotect partners with Chronolife for the development and production of a device to measure physiological data, integrated into a firefighter’s intervention suit to limit the risk of thermal stress March 13, 2022
  • OdySight, first remote monitoring solution in ophthalmology to be reimbursed by the Social Security March 9, 2022

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved